Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population
Authors:
- 20 June 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (6) , 1289-1298
Abstract
The platelet endothelial aggregation receptor‐1 (PEAR1) rs12041331 variant has been identified as a genetic determinant of platelet aggregation in response to antiplatelet therapies, including aspirin. However, association with atherothrombotic cardiovascular events is less clear, with limited evidence from large trials. Here, we tested association of rs12041331 with cardiovascular events and aspirin use in a randomized trial population of healthy older individuals. We undertook post hoc analysis of 13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, median age 74 years. Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrollment, and were randomized to either 100 mg daily low‐dose aspirin or placebo for median 4.7 years follow‐up. We used Cox proportional hazard regression to model the relationship between rs12041331 and the ASPREE primary cardiovascular disease (CVD) end point, and composites of major adverse cardiovascular events (MACE) and ischemic stroke (STROKE); and bleeding events; major hemorrhage (MHEM) and intracranial bleeding (ICB). We performed whole‐population analysis using additive and dominant inheritance models, then stratified by treatment group. Interaction effects between genotypes and treatment group were examined. We observed no statistically significant association (P < 0.05) in the population, or by treatment group, between rs12041331 and cardiovascular or bleeding events in either model. We also found no significant interaction effects between rs12041331‐A and treatment group, for CVD (P = 0.65), MACE (P = 0.32), STROKE (P = 0.56), MHEM (P = 0.59), or ICB (P = 0.56). The genetic variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low‐dose aspirin in a healthy elderly population.Keywords
Funding Information
- National Institute on Aging (U01AG029824, R01HL137922, 334047, 1127060, R01HL137922)
- Medical Research Council
- Monash University
- Victorian Cancer Agency
- Bayer
- Heart Foundation
- National Institutes of Health
This publication has 36 references indexed in Scilit:
- PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathwayBlood, 2013
- Genetic Variation in PEAR1 Is Associated With Platelet Aggregation and Cardiovascular OutcomesCirculation: Cardiovascular Genetics, 2013
- A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1Blood, 2012
- Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expressionBlood, 2011
- Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonistsNature Genetics, 2010
- Glial precursors clear sensory neuron corpses during development via Jedi-1, an engulfment receptorNature Neuroscience, 2009
- A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated With Increased Platelet AggregabilityArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Heritability of Platelet Responsiveness to Aspirin in Activation Pathways Directly and Indirectly Related to Cyclooxygenase-1Circulation, 2007
- Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin TherapyJAMA, 2006
- Platelet Endothelial Aggregation Receptor 1 (PEAR1), a Novel Epidermal Growth Factor Repeat-containing Transmembrane Receptor, Participates in Platelet Contact-induced ActivationJournal of Biological Chemistry, 2005